Afifi et al. (2022) claim that the β‐sitosterol glucoside‐loaded nanosystems (self‐nanoemulsifying drug delivery systems (SEDDS)) have the potential to slow the progression of diabetes in streptozotocin‐induced hyperglycemic rats by reducing insulin resistance, protecting against oxidative stress, and restoring pancreatic β‐cell secretory function. Here, INS is linked to diabetes mellitus.